Untitled

Malaria Acquired in Haiti 2010
Travel Medicine; Public Health; World Health; Malaria; Infectious Diseases FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION Complete PCV7 Vaccination
emergency responders in Haiti are at sub- of P. falciparum malaria acquired in Haiti.
is recommended through age 71 months.
Haitian residents, and one U.S. traveler.
coccal polysaccharide vaccine (PPSV23).
after the last dose of PCV7 or PPSV23.
patients were moderately to seriously ill and mechanical ventilation for acute res- age insert for precautions, warnings, and equipment (e.g., insect repellent and in- REFERENCES
Malaria Acquired
in Haiti—2010
of these eight patients (including thetwo hospitalized military personnel) re- available in a provider’s office is PCV7, typicallynotallcasesarereportedtoCDC.
Reported by: K Mung, MD, B Renamy, MSc, Pan
American Health Organization. JF Vely, MD, R Ma- gloire MD, Ministry of Public Health and Population, Haiti. N Wells, MD, US Navy Medical Corps, J Fer- caused by Plasmodium falciparum infec- guson, DO, US Army Medical Corps. D Townes, MD, tion is endemic in Haiti, and the principal M McMorrow, MD, K Tan, MD, B Divine, L Slutsker, MD, Malaria Br, Div of Parasitic Diseases, Center for mosquito vector is Anopheles albimanus, 2028 JAMA, May 26, 2010—Vol 303, No. 20 (Reprinted) 2010 American Medical Association. All rights reserved.
FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION CDC Editorial Note: In 2008, a total
and doxycycline, tetracycline, or clinda- P. falciparum; all but two of the ma- moprophylaxis in Haiti, a change to a dif- United States from areas in Africa, Asia, are started Ͻ1 week before departure, or while already in Haiti, either atovaquone- Plasmodium species that routinely in- fect humans (P. falciparum, P. vivax, P. malariae, and P. ovale), P. falciparum loquine requires receiving the initial dose or clinical deterioration. Severe malaria ing protective clothing, and sleeping un- quinidine and one of the following: doxy- der an insecticide-treated mosquito net.
cycline, tetracycline, or clindamycin. In- fective in preventing malaria, is not 100% effective. Therefore, if fever develops in as part of an investigational drug proto- sponder in the field, treatment should be still should be evaluated for malaria in- an overall prevalence of P. falciparum laria smears spaced 12-24 hours apart are that country’s national treatment guide- formation on parasite drug susceptibility for a specific geographic setting. In Haiti, nosis of malaria is not possible, presump- chloroquine. No evidence exists of clini- cion of malaria (e.g., unexplained fever) persons with P. falciparum infection ac- used to assess treatment failure in a pa- Persons with laboratory-confirmed P. P. falciparum isolates collected in the Ar- falciparum malaria acquired in Haiti and tibonite Valley in Haiti in 2006 and 2007 though the findings do not serve as a ba- laria can be treated with one of the fol- REFERENCES
2010 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 26, 2010—Vol 303, No. 20 2029

Source: http://www.medicalstudentmissions.org/MSM/Blog/Entries/2010/7/27_Some_Light_Reading_files/Malaria%20in%20Haiti.pdf